848472-36-6

Basic information

• Product Name: CARBAMIC ACID, N-(4,6-DIMETHYL-2-PYRIDINYL)-,1,1-DIMETHYLETHYL ESTER
• Synonyms: CARBAMIC ACID, N-(4,6-DIMETHYL-2-PYRIDINYL)-,1,1-DIMETHYLETHYL ESTER;(4,6-Dimethyl-2-pyridinyl)carbamic acid tert-butyl ester;2-(Boc-amino)-4,6-dimethylpyridine;tert-Butyl (4,6-dimethyl-2-pyridinyl)carbamate
• CAS NO: 848472-36-6
• Molecular Formula: C₁₂H₁₈N₂O₂
• Molecular Weight: 222.286
• Mol File: 848472-36-6.mol

Chemical Properties

• Melting Point: 75-79°C
• Appearance: /
• CAS DataBase Reference: CARBAMIC ACID, N-(4,6-DIMETHYL-2-PYRIDINYL)-,1,1-DIMETHYLETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: CARBAMIC ACID, N-(4,6-DIMETHYL-2-PYRIDINYL)-,1,1-DIMETHYLETHYL ESTER(848472-36-6)
• EPA Substance Registry System: CARBAMIC ACID, N-(4,6-DIMETHYL-2-PYRIDINYL)-,1,1-DIMETHYLETHYL ESTER(848472-36-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 848472-36-6(Hazardous Substances Data)

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 5407-87-4 2-Amino-4,6-dimethylpyridine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1329998-86-8 (3R,4R)-tert-butyl 3-((6-(bis(tert-butoxycarbonyl)amino)-4-methyl-2-pyridyl)methyl)-4-(2-((2,2-difluoro-2-(3-fluorophenyl)ethyl)amino)ethoxy)pyrrolidine-1-carboxylate 
• 1329998-87-9 (3R,4R)-tert-butyl 3-((6-(bis(tert-butoxycarbonyl)amino)-4-methylpyridin-2-yl)methyl)-4-(2-((2,2-difluoro-2-(3-chlorophenyl)ethyl)amino)ethoxy)pyrrolidine-1-carboxylate 
• 1329998-88-0 (3R,4R)-tert-butyl 3-((6-(bis(tert-butoxycarbonyl)amino)-4-methylpyridin-2-yl)methyl)-4-(2-((2,2-difluoro-2-(2-chlorophenyl)ethyl)amino)ethoxy)pyrrolidine-1-carboxylate 
• 1329998-89-1 C₃₆H₅₂F₂N₄O₇ 
• 1329998-90-4 C₃₆H₅₀ClF₃N₄O₇ 
• 1329998-91-5 C₃₆H₅₀F₄N₄O₇ 
• 1018909-81-3 (3S,4S)-tert-butyl 3-{{6-[benzyl(tert-butoxycarbonyl)amino]-4-methylpyridin-2-yl}methyl}-4-{(1S,4R)-4,7,7-trimethyl-3-oxo-oxabicyclo[2.2.1]heptane-1-carbonyloxy}pyrrolidine-1-carboxylate 
• 1018909-82-4 (3R,4R)-tert-butyl 3-{{6-[benzyl(tert-butoxycarbonyl)amino]-4-methylpyridin-2-yl}methyl}-4-{(1S,4R)-4,7,7-trimethyl-3-oxo-oxabicyclo[2.2.1]heptane-1-carbonyloxy}pyrrolidine-1-carboxylate 
• 1018909-83-5 (3'S,4'S)-tert-butyl 3'-{{6''-[benzyl(tert-butoxycarbonyl)-amino]-4''-methylpyridin-2''-yl}methyl}-4'-hydroxypyrrolidine-1'carboxylate 
• 1018909-84-6 (3'R,4'R)-tert-butyl 3'-{{6''-[benzyl(tert-butoxycarbonyl)-amino]-4''-methylpyridin-2''-yl}methyl}-4'-hydroxypyrrolidine-1'carboxylate 
• 1018909-99-3 (3R,4S)-tert-butyl 3-azido-4-{{6-[benzyl(tert-butoxycarbonyl)amino]-4-methylpyridin-2-yl}methyl}-4-hydroxypyrrolidine-1-carboxylate 
• 1018910-01-4 (3R,4S)-tert-butyl 3-(2-(tert-butoxycarbonyl(3-fluorophenethyl)amino)ethylamino)-4-((6-(tert-butoxycarbonylamino)-4-methylpyridin-2-yl)methyl)pyrrolidine-1-carboxylate 
• 1386976-13-1 tert-butyl (Z)-benzyl-(6-(5-bromopent-3-en-1-yl)-4-methylpyridin-2-yl)carbamate 

Relevant articles and documents

Overcoming mutagenicity and ion channel activity: Optimization of selective spleen tyrosine kinase inhibitors

Development of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable druglike properties is described. Early leads were discovered through X-ray crystallographic analysis, and a systematic survey of cores within a selected chemical space focused on ligand binding efficiency. Attenuation of hERG ion channel activity inherent within the initial chemotype was guided through modulation of physicochemical properties including log D, PSA, and pKa. PSA proved most effective for prospective compound design. Further profiling of an advanced compound revealed bacterial mutagenicity in the Ames test using TA97a Salmonella strain, and subsequent study demonstrated that this mutagenicity was pervasive throughout the series. Identification of intercalation as a likely mechanism for the mutagenicity-enabled modification of the core scaffold. Implementation of a DNA binding assay as a prescreen and models in DNA allowed resolution of the mutagenicity risk, affording molecules with favorable potency, selectivity, pharmacokinetic, and off-target profiles.

SPECIFIC NNOS INHIBITORS FOR THE THERAPY AND PREVENTION OF HUMAN MELANOMA

Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies.

Exploration of the active site of neuronal nitric oxide synthase by the design and synthesis of pyrrolidinomethyl 2-aminopyridine derivatives

Neuronal nitric oxide synthase (nNOS) represents an important therapeutic target for the prevention of brain injury and the treatment of various neurodegenerative disorders. A series of trans-substituted amino pyrrolidinomethyl 2-aminopyridine derivatives

Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping

Selective inhibition of neuronal nitric oxide synthase (nNOS) has been shown to prevent brain injury and is important for the treatment of various neurodegenerative disorders. This study shows that not only greater inhibitory potency and isozyme selectivity but more druglike properties can be achieved by fragment hopping. On the basis of the structure of lead molecule 6, fragment hopping effectively extracted the minimal pharmacophoric elements in the active site of nNOS for ligand hydrophobic and steric interactions and generated appropriate lipophilic fragments for lead optimization. More potent and selective inhibitors with better druglike properties were obtained within the design of 20 derivatives (compounds 7-26). Our structure - based inhibitor design for nNOS and SAR analysis reveal the robustness and efficiency of fragment hopping in lead discovery and structural optimization, which implicates a broad application of this approach to many other therapeutic targets for which known druglike small-molecule modulators are still limited.

NOS INHIBITORS FOR TREATMENT OF MOTOR DEFICIT DISORDERS

The present invention relates to preventive therapies and treatments of motor deficit disorders. In particular, the present invention relates to compositions and methods for preventative therapy and treatment of motor deficit disorders, such as cerebral p

POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE

Peptidomimetic compounds as can inhibit neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as but not limited to stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease.